Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bristol Myers Squibb Company

https://www.bms.com/

Latest From Bristol Myers Squibb Company

Biopharma Industry Sharply Divided Over Supreme Court Antibody Patent Brawl

Big biologic makers line up on opposite sides of dispute between Amgen and Sanofi over whether Amgen’s Repatha patents cover analogous antibodies with the same functional characteristics.

Biologics Intellectual Property

89bio’s Phase IIb Data Heighten Competition Within NASH FGF21 Analog Class

89bio’s pegozafermin met co-primary endpoints of fibrosis reduction and NASH resolution in Phase IIb; the company said its methodology yielded lower placebo responses than in Akero’s Phase IIb study.

Clinical Trials Business Strategies

Biohaven Makes Bet On Brain-Penetrant TYK2/JAK1 Inhibitor For Neurological Diseases

The company, which has struggled in the clinic following a deal where Pfizer bought its migraine portfolio, is licensing the dual inhibitor drug from a Chinese firm for up to $970m.

Deals Business Strategies

As Japan’s Syphilis Cases Surge, So Do Calls For More Therapeutics

As Japan faces skyrocketing syphilis cases, hopes have been high among domestic physicians for a single-dose therapeutic in the form of benzylpenicillin injection. But the country has approved the drug only recently and in answer to a push from doctors on the front line.

Japan Infectious Diseases
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Abraxis BioScience, Inc.
    • AbVitro, Inc.
    • Acetylon Pharmaceuticals, Inc.
    • Adnexus Therapeutics, Inc.
    • Allied-Bristol Life Sciences, LLC
    • Amira Pharmaceuticals, Inc.
    • Amylin Pharmaceuticals, Inc.
    • Avila Therapeutics, Inc.
    • Bristol-Myers Company
    • Bristol-Myers K.K.
    • Bristol-Myers Squibb
    • Cardioxyl Pharmaceuticals
    • Celgene Corporation
    • Cormorant Pharmaceuticals
    • Delinia, Inc.
    • EngMab AG
    • Flexus Biosciences, Inc.
    • Gloucester Pharmaceuticals, Inc.
    • ißeCa Therapeutics
    • IFM Therapeutics
    • Impact Biomedicines, Inc.
    • Inhibitex, Inc.
    • iPierian Inc.
    • Juno Therapeutics, Inc.
    • Juno Therapeutics GmbH (Stage Cell Therapeutics GmbH)
    • JW Biotechnology (Shanghai) Co., Ltd
    • Kosan
    • Medarex, Inc.
    • Padlock Therapeutics, Inc.
    • Pharmion Corporation
    • Quanticel Pharmaceuticals, Inc.
    • Receptos, Inc.
    • RedoxTherapies, Inc.
    • Turning Point Therapeutics Inc.
    • Westwood-Squibb Pharmaceuticals
    • X-BODY, Inc.
    • ZymoGenetics, Inc.
    • Forbius
    • MyoKardia Inc.
UsernamePublicRestriction

Register